Kynurenine pathway metabolites as biomarkers for Amyotrophic Lateral Sclerosis

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Amyotrophic Lateral Sclerosis (ALS) currently lacks a robust and well-defined biomarker that can 1) assess the progression of the disease, 2) predict and/or delineate the various clinical subtypes, and 3) evaluate or predict a patient’s response to treatments. The kynurenine Pathway (KP) of tryptophan degradation represent a promising candidate as it is involved with several neuropathological features present in ALS including neuroinflammation, excitotoxicity, oxidative stress, immune system activation and dysregulation of energy metabolism. Some of the KP metabolites (KPMs) can cross the blood brain barrier, and many studies have shown their levels are dysregulated in major neurodegenerative diseases including ALS. The KPMs can be easily analyzed in body fluids and tissue and as they are small molecules, and are stable. KPMs have a Janus face action, they can be either or both neurotoxic and/or neuroprotective depending of their levels. This mini review examines and presents evidence supporting the use of KPMs as a relevant set of biomarkers for ALS, and highlights the criteria required to achieve a valid biomarker set for ALS.

LanguageEnglish
Article number1013
Pages1-11
Number of pages11
JournalFrontiers in Neuroscience
Volume13
DOIs
Publication statusPublished - 20 Sep 2019

Fingerprint

Kynurenine
Amyotrophic Lateral Sclerosis
Biomarkers
Body Fluids
Blood-Brain Barrier
Tryptophan
Neurodegenerative Diseases
Energy Metabolism
Disease Progression
Immune System
Oxidative Stress

Bibliographical note

Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • amyotrophic lateral sclerosis
  • biomarker development
  • kynurenine pathway
  • motor neuron disease
  • neurodegeneration
  • neuroinflammation and neurodegeneration
  • tryptophan

Cite this

@article{9cad8dc1d8e340eb928b40045e59afdc,
title = "Kynurenine pathway metabolites as biomarkers for Amyotrophic Lateral Sclerosis",
abstract = "Amyotrophic Lateral Sclerosis (ALS) currently lacks a robust and well-defined biomarker that can 1) assess the progression of the disease, 2) predict and/or delineate the various clinical subtypes, and 3) evaluate or predict a patient’s response to treatments. The kynurenine Pathway (KP) of tryptophan degradation represent a promising candidate as it is involved with several neuropathological features present in ALS including neuroinflammation, excitotoxicity, oxidative stress, immune system activation and dysregulation of energy metabolism. Some of the KP metabolites (KPMs) can cross the blood brain barrier, and many studies have shown their levels are dysregulated in major neurodegenerative diseases including ALS. The KPMs can be easily analyzed in body fluids and tissue and as they are small molecules, and are stable. KPMs have a Janus face action, they can be either or both neurotoxic and/or neuroprotective depending of their levels. This mini review examines and presents evidence supporting the use of KPMs as a relevant set of biomarkers for ALS, and highlights the criteria required to achieve a valid biomarker set for ALS.",
keywords = "amyotrophic lateral sclerosis, biomarker development, kynurenine pathway, motor neuron disease, neurodegeneration, neuroinflammation and neurodegeneration, tryptophan",
author = "Tan, {Vanessa X.} and Guillemin, {Gilles J.}",
note = "Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2019",
month = "9",
day = "20",
doi = "10.3389/fnins.2019.01013",
language = "English",
volume = "13",
pages = "1--11",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Media S.A.",

}

Kynurenine pathway metabolites as biomarkers for Amyotrophic Lateral Sclerosis. / Tan, Vanessa X.; Guillemin, Gilles J.

In: Frontiers in Neuroscience, Vol. 13, 1013, 20.09.2019, p. 1-11.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Kynurenine pathway metabolites as biomarkers for Amyotrophic Lateral Sclerosis

AU - Tan, Vanessa X.

AU - Guillemin, Gilles J.

N1 - Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2019/9/20

Y1 - 2019/9/20

N2 - Amyotrophic Lateral Sclerosis (ALS) currently lacks a robust and well-defined biomarker that can 1) assess the progression of the disease, 2) predict and/or delineate the various clinical subtypes, and 3) evaluate or predict a patient’s response to treatments. The kynurenine Pathway (KP) of tryptophan degradation represent a promising candidate as it is involved with several neuropathological features present in ALS including neuroinflammation, excitotoxicity, oxidative stress, immune system activation and dysregulation of energy metabolism. Some of the KP metabolites (KPMs) can cross the blood brain barrier, and many studies have shown their levels are dysregulated in major neurodegenerative diseases including ALS. The KPMs can be easily analyzed in body fluids and tissue and as they are small molecules, and are stable. KPMs have a Janus face action, they can be either or both neurotoxic and/or neuroprotective depending of their levels. This mini review examines and presents evidence supporting the use of KPMs as a relevant set of biomarkers for ALS, and highlights the criteria required to achieve a valid biomarker set for ALS.

AB - Amyotrophic Lateral Sclerosis (ALS) currently lacks a robust and well-defined biomarker that can 1) assess the progression of the disease, 2) predict and/or delineate the various clinical subtypes, and 3) evaluate or predict a patient’s response to treatments. The kynurenine Pathway (KP) of tryptophan degradation represent a promising candidate as it is involved with several neuropathological features present in ALS including neuroinflammation, excitotoxicity, oxidative stress, immune system activation and dysregulation of energy metabolism. Some of the KP metabolites (KPMs) can cross the blood brain barrier, and many studies have shown their levels are dysregulated in major neurodegenerative diseases including ALS. The KPMs can be easily analyzed in body fluids and tissue and as they are small molecules, and are stable. KPMs have a Janus face action, they can be either or both neurotoxic and/or neuroprotective depending of their levels. This mini review examines and presents evidence supporting the use of KPMs as a relevant set of biomarkers for ALS, and highlights the criteria required to achieve a valid biomarker set for ALS.

KW - amyotrophic lateral sclerosis

KW - biomarker development

KW - kynurenine pathway

KW - motor neuron disease

KW - neurodegeneration

KW - neuroinflammation and neurodegeneration

KW - tryptophan

UR - http://www.scopus.com/inward/record.url?scp=85073037404&partnerID=8YFLogxK

U2 - 10.3389/fnins.2019.01013

DO - 10.3389/fnins.2019.01013

M3 - Review article

VL - 13

SP - 1

EP - 11

JO - Frontiers in Neuroscience

T2 - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

M1 - 1013

ER -